KA
LFCR icon

Keene & Associates’s Lifecore Biomedical LFCR Stock Holding History

Keene & Associates’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,410
Closed -$110K – 79
2024
Q3 		$110K Hold
22,410
– – 0.08% 75
2024
Q2 		$115K Hold
22,410
– – 0.09% 72
2024
Q1 		$119K Buy
22,410
+475
+2% +$3.4K 0.09% 79
2023
Q4 		$136K Sell
21,935
-2,000
-8% -$13.9K 0.11% 77
2023
Q3 		$181K Sell
23,935
-165
-0.7% -$1.51K 0.14% 78
2023
Q2 		$233K Hold
24,100
– – 0.18% 74
2023
Q1 		$91K Buy
24,100
+10,700
+80% +$59.6K 0.07% 76
2022
Q4 		$86.8K Sell
13,400
-12,800
-49% -$105K 0.08% 73
2022
Q3 		$233K Hold
26,200
– – 0.21% 71
2022
Q2 		$261K Buy
26,200
+3,455
+15% +$34.2K 0.24% 66
2022
Q1 		$263K Buy
22,745
+4,790
+27% +$53.3K 0.21% 71
2021
Q4 		$199K Buy
+17,955
New +$174K 0.17% 76

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Keene & Associates's LFCR Position: Q4 2024 in Review

Keene & Associates sold out of Lifecore Biomedical (LFCR) in Q4 2024, closing a stake of 22,410 shares — an estimated $110K sold.

Keene & Associates first reported a position in LFCR in Q4 2021 and held it in 12 quarters. The position peaked at $263K in Q1 2022. 77 funds tracked by Wall St. Rank hold LFCR as of Q4 2024.

  • Keene & Associates reported no remaining Lifecore Biomedical position as of Q4 2024 after selling out during the quarter.
  • Keene & Associates sold 22,410 Lifecore Biomedical shares in Q4 2024, an estimated $110K.
  • Keene & Associates first reported a position in Lifecore Biomedical in Q4 2021 and held it in 12 quarters.
  • Keene & Associates's Lifecore Biomedical position peaked at $263K in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.